290 related articles for article (PubMed ID: 34829513)
1. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine.
Vernuccio F; Messina C; Merz V; Cannella R; Midiri M
Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829513
[TBL] [Abstract][Full Text] [Related]
2. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
4. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
5. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
6. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
7. Definition and Management of Borderline Resectable Pancreatic Cancer.
Denbo JW; Fleming JB
Surg Clin North Am; 2016 Dec; 96(6):1337-1350. PubMed ID: 27865281
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
9. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
12. Imaging for pancreatic ductal adenocarcinoma.
Horvat N; Ryan DE; LaGratta MD; Shah PM; Do RK
Chin Clin Oncol; 2017 Dec; 6(6):62. PubMed ID: 29307202
[TBL] [Abstract][Full Text] [Related]
13. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
14. A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma.
Hester CA; Katz MHG
Chin Clin Oncol; 2022 Dec; 11(6):45. PubMed ID: 36509553
[TBL] [Abstract][Full Text] [Related]
15. Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center.
Curto EM; Kaza AG; Sturdevant DA; Tuvin DM; Ganai S; Sticca RP
Am J Surg; 2022 Dec; 224(6):1426-1431. PubMed ID: 36372580
[TBL] [Abstract][Full Text] [Related]
16. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
18. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Sulciner ML; Ashley SW; Molina G
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
20. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]